24418-86-8
24418-86-8 結(jié)構(gòu)式
基本信息
2-(3,4-二羥基亞芐基)苯并呋喃-3(2H)-酮
Sphingosine Kinase Inhibitor V
2-(3,4-Dihydroxy-benzylidene)-benzofuran-3-one
2-(3,4-Dihydroxybenzylidene)benzofuran-3(2H)-one
3(2H)-Benzofuranone, 2-[(3,4-dihydroxyphenyl)methylene]-
(2Z)-2-(3,4-dihydroxybenzylidene)-1-benzofuran-3(2H)-one
(2E)-2-[(3,4-dihydroxyphenyl)methylidene]-1-benzofuran-3-one
2-(3,4-Dihydroxy-benzylidene)-benzofuran-3-one, Sphingosine Kinase Inhibitor V
物理化學(xué)性質(zhì)
| 報(bào)價(jià)日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價(jià)格 |
| 2024/11/08 | HY-12895 | 2-(3,4-二羥基亞芐基)苯并呋喃-3(2H)-酮 SKI V | 24418-86-8 | 5mg | 1500元 |
| 2024/11/08 | HY-12895 | 2-(3,4-二羥基亞芐基)苯并呋喃-3(2H)-酮 SKI V | 24418-86-8 | 10mM * 1mLin DMSO | 1650元 |
| 2024/11/08 | HY-12895 | 2-(3,4-二羥基亞芐基)苯并呋喃-3(2H)-酮 SKI V | 24418-86-8 | 10mg | 2500元 |
常見問題列表
IC50: 2 μM (GST-hSK), 6 μM (hPI3k) and 80 μM (ERK2)
SKI V has weak activity toward ERK2 (
IC
50
of 80 μM for hERK2) and does not inhibit PKC-α.
SKI V (10 μM; for 24 hours) inhibits cancer cell proliferation and induces apoptosis.
SKI V (0.2, 1, 5 μM; pretreated for 1 hour) decreases phospho-Akt and phospho-MEK levels. Near-confluent cultures of JC cells are serum-starved for 16 hours, followed by pretreatment SKI V for 1 hour.
SKI V has IC
50
s for inhibition of sphingosine kinase (SK) and tumor cell proliferation of ～2 μM.
SKI V (20 μg/ml) inhibits not only purified but endogenous SK in in MDA-MB-231 cells.
SKI V (0.2, 1, 5 μM) inhibits intracellular S1P formation in JC cells in a dose-dependent fashion.
Cell Proliferation Assay
| Cell Line: | T24 tumor cells |
| Concentration: | 10 μM |
| Incubation Time: | For 24 hours |
| Result: | Inhibited cancer cell proliferation. |
Apoptosis Analysis
| Cell Line: | T24 tumor cells |
| Concentration: | 10 μM |
| Incubation Time: | For 24 hours |
| Result: | Induced apoptosis. |
Western Blot Analysis
| Cell Line: | JC cells |
| Concentration: | 0.2, 1, 5 μM |
| Incubation Time: | Pretreated for 1 hour |
| Result: | Decreased phospho-Akt and phospho-MEK levels. |
SKI V (75 mg/kg; i.p.; days 1, 5, 9, 15) significantly lowers tumor growth (>50% decreased at day 18) than control animals.
| Animal Model: | 6-8 weeks old BALB/c female mice with JC mammary adenocarcinoma cells |
| Dosage: | 75 mg/kg |
| Administration: | IP; days 1, 5, 9, 15 |
| Result: | Tumor growth was significantly lower (>50% decreased at day 18) than tumor growth in control animals. |